Ombitasvir/paritaprevir/ritonavir

Phase 3Small molecule

Ombitasvir/paritaprevir/ritonavir is one of 181 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

180

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Hepatitis CActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Chronic Hepatitis C Virus InfectionActive, not recruiting

Hepatitis C Virus InfectionActive, not recruiting

Chronic HepatitisPhase 3

Active, not recruiting

Hepatocellular CarcinomaPhase 3

Active, not recruiting

Hepatitis CPhase 3

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Chronic Hepatitis C Virus InfectionPhase 3

Active, not recruiting

Hepatitis C Virus InfectionPhase 3

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ombitasvir/paritaprevir/ritonavir

AbbVie

Phase 3

1 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Ibrance

Pfizer

Preclinical

1 4

Viread

Gilead

Preclinical

1 5

Sovaldi

Gilead

Preclinical

1 6

Hepsera

Gilead

Preclinical

—7

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 8

Doptelet

AAkarx

Preclinical

1 9

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis11 trials

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Completed· AbbVie logo

AbbVie··NCT02581163·314 enrolled

A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02216422·36 enrolled

ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02517515·650 enrolled

Show 8 more trials

A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients

Completed· AbbVie logo

AbbVie·Phase 2·NCT01782495·129 enrolled

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland

Completed· AbbVie logo

AbbVie··NCT02582671·101 enrolled

A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)

Completed· AbbVie logo

AbbVie·Phase 3·NCT02265237·184 enrolled

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02219503·60 enrolled

Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)

Withdrawn· AbbVie logo

AbbVie·Phase 3·NCT02806362

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT02487199·18 enrolled

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

Completed· AbbVie logo

AbbVie··NCT02581189·565 enrolled

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

Completed· AbbVie logo

AbbVie··NCT02803138·256 enrolled

Chronic Hepatitis C Virus Infection4 trials

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02442284·99 enrolled

A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection

Completed· AbbVie logo

AbbVie·Phase 2·NCT02356562·29 enrolled

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02609659·105 enrolled

Show 1 more trial

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02219477·36 enrolled

Hepatitis C Virus Infection2 trials

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil

Completed· AbbVie logo

AbbVie·Phase 3·NCT02442271·222 enrolled

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

Completed· AbbVie logo

AbbVie·Phase 2/3·NCT02486406·64 enrolled

Hepatitis C2 trials

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Completed· AbbVie logo

AbbVie·Phase 3·NCT02476617·25 enrolled

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

Completed· AbbVie logo

AbbVie·Phase 3·NCT02582632·166 enrolled

Hepatocellular Carcinoma1 trial

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

Terminated· AbbVie logo

AbbVie·Phase 3·NCT02504099·3 enrolled

4 more indications

EGFR1 trial

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Completed·NNational Taiwan University Hospital··NCT04047680·441 enrolled

Age1 trial

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

Completed·—·N/A·NCT03549832·40 enrolled

Chronic Kidney Disease1 trial

Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT02207088·68 enrolled

Treatment1 trial

Effect Of DAAs For Treatment Of HCV On Normal Kidney

Unknown status·—·Phase 4·NCT03296930·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for Ombitasvir/paritaprevir/ritonavir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ombitasvir/paritaprevir/ritonavir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ombitasvir/paritaprevir/ritonavir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

Ombitasvir/paritaprevir/ritonavir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis11 trials

Chronic Hepatitis C Virus Infection4 trials

Hepatitis C Virus Infection2 trials

Hepatitis C2 trials

Hepatocellular Carcinoma1 trial

EGFR1 trial

Age1 trial

Chronic Kidney Disease1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News